• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / RESEARCH . . . . / Gardasil/Silgard Vaccine / Gardasil/Silgard Reactions / Early cervical myelitis after human papilloma virus vaccination

Early cervical myelitis after human papilloma virus vaccination

April 8, 2015 By Norma Leave a Comment

Authors: Mireya Fernández-Fournier, MD, Javier Díaz de Terán, MD, Antonio Tallón Barranco, MD, PhD and Inmaculada Puertas, MD, PhD

In 2006, an adjuvant vaccine against 4 human papillomavirus (HPV) types was licensed. By 2012, 45 countries had introduced HPV vaccination.1 HPV encompasses a group of more than 100 viruses, of which at least 13 are high-risk types, responsible for cervical and other anogenital cancers.2 There are currently 2 vaccines that prevent HPV 16 and 18 infection (known to cause 70% of cervical cancers) and development of subsequent cervical precancerous lesions.1

Case report

A 14-year-old immunocompetent girl noticed her left hand felt weak and numb. These symptoms spread over 5 days to the rest of her arm and ipsilateral thoracic region, abdomen, and leg. Three days earlier she had received a first dose of quadrivalent HPV recombinant vaccine (qHPV, Gardasil). She had not had fever or previous symptoms suggestive of infection. On examination, she had bilateral diminished sensation to light touch, pain, and vibration below C5 level; muscle weakness of her left arm and leg, being able to move joints against resistance (grade 4 according to the Medical Research Council scale for muscle strength); and hyperreflexia bilaterally with nonsustained clonus and a left extensor plantar response. Neurologic examination was otherwise normal.

Brain and cervical spine MRI revealed an isolated C1-C2 hyperintense lesion in T2-weighted images (figure). CSF analysis showed normal glucose (0.49 mg/dL) and protein levels without cells, an increased myelin basic protein (6.4 ng/mL), an increased nonspecific immunoglobulin M ratio, and the presence of oligoclonal bands. Serology and PCR ruled out infectious etiologies, with negative testing for Borrelia, Treponema, Listeria, herpesviruses 1, 2, and 6, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, and HIV. Laboratory screening showed normal angiotensin-converting enzyme, vitamin B12, and folate levels and was negative for antinuclear and antitransglutaminase antibodies.

Figure

View larger version:

  • In a new window
  • Download as PowerPoint Slide

FIGURE Brain and cervical spine MRIs showing an isolated C1-C2 lesion

Brain MRI T2-weighted images: axial (A) and coronal (B) images showing absence of brain lesions. Cervical MRI T2-weighted images: axial (C) and sagittal (D) images showing an isolated C1-C2 hyperintense lesion.

Cervical transverse myelitis was diagnosed. Treatment with 1 g IV methylprednisolone was given for 5 days and clinical improvement ensued. Six months later, only mild left hand hypoesthesia and lower extremity hyperreflexia persisted. Follow-up brain and spinal MRI revealed an improvement of the cervical lesion without development of new lesions.

Discussion

HPV infection is transmitted mainly through sexual contact and it is a necessary step in the pathogenesis of cervical cancers. Cervical cancer is the second most common cancer in women and causes more than 270,000 deaths per year, mostly in low- and middle-income countries.1 In the United States, there are an estimated 11,000 newly diagnosed cases of HPV-associated cervical cancer and 4,000 resulting deaths annually.3 The World Health Organization recommends vaccination for girls aged 9–13 years as “the most cost-effective public health measure against cervical cancer.”1 However, there are safety concerns regarding HPV vaccines.

The relationship between HPV vaccination and subsequent CNS inflammation remains unclear. A recent review summarizes 9 published cases of CNS demyelination following HPV vaccination; clinical syndromes vary and include myelitis, optic neuritis, and encephalitis.4 In the genesis of CNS inflammatory disorders post-HPV vaccination, both molecular mimicry between vaccine antigen and myelin proteins and toxic materials in vaccine components are seen as potential causative factors.5 There are previous reports of CNS inflammatory syndromes following HPV vaccination describing a 10-day to 5-month time lapse from vaccination to symptom onset, with a minimum of a 21-day interval in cases developing myelitis. Recent reviews on this topic did not find an increased rate of subsequent autoimmune diseases; nevertheless, they acknowledge limitations regarding statistical power6 and data concerning specific populations.7

We present a case of transverse myelitis 3 days after HPV immunization. To our knowledge, this is the earliest case of CNS inflammation following HPV immunization, with a less than 7-day interval from vaccination to symptom onset. Regarding etiology, the patient was immunocompetent and there were no systemic signs of infection. The absence of cells in CSF analysis and the presence of oligoclonal bands with an increased nonspecific immunoglobulin M ratio suggested a background of a CNS inflammatory condition; however, the mechanism of disease, whether viral-induced or immune-mediated, remains to be determined.

In conclusion, the probable benefits of mass vaccination with HPV seem to outweigh the potential risks. However, we must continue to report and investigate cases of inflammatory disorders of the CNS associated with qHPV vaccination, both for safety reasons and because it may help comprehend the pathogenesis of subsequent CNS demyelination.

ACKNOWLEDGMENTS

Acknowledgement: The authors thank the Neurology Department at La Paz University Hospital, especially Dr. Olga Trabajos, MD, who provided careful patient care and assistance during the patient’s hospitalization.

FOOTNOTES

  • Author contributions: Dr. Fernández-Fournier: conceptualization and manuscript drafting. Dr. Díaz de Terán: manuscript drafting. Dr. Tallón Barranco: manuscript revision. Dr. Puertas: manuscript revision.

  • Study funding: No targeted funding reported.

  • Disclosure: The authors report no disclosures. Go to Neurology.org/nn for full disclosures. The Article Processing Charge was paid by Fundación Investigación Biomédica del Hospital La Paz.

  • Received June 20, 2014.
  • Accepted in final form August 6, 2014.
  • © 2014 American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Access original article here, complete with references.

Related

Filed Under: Gardasil/Silgard Reactions Tagged With: central nervous system inflammation, cervical myelitis, HPV vaccination

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Kahlia from New Zealand

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

Forced Child Vaccinations Without Parents Consent

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2025 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in